AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1064902
Drug: Rapidly-disintegrating ferrous
RxNorm normalized name: Ferrous Fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapidly-disintegrating ferrous sulphate tablets
Trial: 1064902
Drug: Ferrous carbonate
RxNorm normalized name: ferrous carbonate
DrugBank: Ferrous carbonate (DB13698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous carbonate tablets
Trial: 1064902
Drug: Slow-release ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release ferrous sulphate tablets
Trial: 1064902
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate solution (reference)
Trial: 26917439
Drug: 6-mm implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mm implants (test group)
Trial: 26917439
Drug: 10-mm implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mm implants (control group)
Trial: 22569050
Drug: Postoperative nasal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative nasal spray regimens (specific regimens not detailed)
Trial: 22569050
Drug: Age, gender,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, gender, and nasal spray regimen
Trial: 20439954
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment of malaria in infants (IPTi) with sulphadoxine‐pyrimethamine
Trial: 30027912
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% solution plus low-level light therapy twice per day
Trial: 30027912
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% solution with a laser comb system turned off (placebo)
Trial: 30027912
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% solution plus low-level light therapy
Trial: 26468161
Drug: Vehicle (l-arginine)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (l-arginine)
Trial: 16088848
Drug: Candesartan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (16 mg, increased to 32 mg after one month)
Trial: 9745827
Drug: Baerveldt glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt glaucoma implant
Trial: 3311145
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of viscous polysaccharides or 'slow-release' carbohydrates
Trial: 29652929
Drug: MVA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA vaccine (Groups 1-3)
Trial: 25613811
Drug: Latanoprost-timolol fixed
RxNorm normalized name: latanoprost / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost-timolol fixed combination (LTFC)
Trial: 21906390
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (HFCWO)
Trial: 16702890
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (37.5-300 mg/d)
Trial: 14692709
Drug: Liverman capsule
RxNorm normalized name: Ivermax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liverman capsule
Trial: 14692709
Drug: Legalon capsule
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Legalon capsule
Trial: 14692709
Drug: Silymarin tablet
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin tablet
Trial: 8922657
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (T3) 20 micrograms three times daily for 7 days
Trial: 23391367
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of arbidol (0.2 g, 0.4 g, 0.8 g)
Trial: 23391367
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of arbidol (0.2 g, 3 times a day for 7 days)
Trial: 12841306
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vitamin C and E
Trial: 9732305
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (7000 microg retinol equivalents weekly)
Trial: 9732305
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (7000 microg retinol equivalents weekly)
Trial: 7666265
Drug: Heparin intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin intake (mean 83.5 units/kg/day)
Trial: 7666265
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin intake (mean 59.4 units/kg/day)
Trial: 2773833
Drug: Moderate nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate nicotine dose (15 micrograms/kg body wt)
Trial: 2773833
Drug: Low nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low nicotine dose (7.5 micrograms/kg body wt)
Trial: 61951
Drug: Benetazone Spofa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benetazone Spofa (trimethazone) 1000 mg/day
Trial: 61951
Drug: Phenylbutazone 600
RxNorm normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 600 mg/day
Trial: 26905330
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by radical surgery (NACT-RS)
Trial: 24984991
Drug: Combined calcium
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined calcium and iron (700 mg Ca as calcium carbonate plus 30 mg Fe as ferrous sulfate)
Trial: 24984991
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation alone (30 mg Fe as ferrous sulfate)
Trial: 19950575
Drug: PAS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAS group (aspirin 100 mg, atorvastatin 10 mg, probucol 0.25 g daily)
Trial: 19950575
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (aspirin 100 mg, atorvastatin 10 mg daily)
Trial: 14692903
Drug: PGB, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGB, 150 mg/day
Trial: 14692903
Drug: PGB, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGB, 600 mg/day
Trial: 11208823
Drug: 12 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12 monthly cycles of adjuvant CMF chemotherapy
Trial: 7877646
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment after radical mastectomy
Trial: 8092756
Drug: Buflomedil infusion
RxNorm normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil infusion
Trial: 28633777
Drug: Superficial corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial corticosteroid injection
Trial: 28633777
Drug: Deep corticosteroid
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep corticosteroid injection
Trial: 17291932
Drug: Intravenous diuretics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diuretics
Trial: 9925061
Drug: n of
RxNorm normalized name: Antigen of mold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n of 1 trials (theophylline therapy)
Trial: 9925061
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice (theophylline therapy)
Trial: 9925061
Drug: n of
RxNorm normalized name: Antigen of mold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n of 1 trials (theophylline treatment)
Trial: 8542870
Drug: Hirudin (DG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (DG I: bolus 0.1 mg.kg‐1 and continuous infusion 0.06 mg.kg‐1.h‐1)
Trial: 8542870
Drug: Hirudin (DG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (DG II: bolus 0.2 mg.kg‐1.h‐1)
Trial: 8542870
Drug: Hirudin (DG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (DG III: bolus 0.4 mg.kg‐1 with 0.15 mg.kg‐1.h‐1)
Trial: 8542870
Drug: Heparin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin as an adjunct to streptokinase and aspirin (control group)
Trial: 30537083
Drug: Fimasartan (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (60 mg once a day)
Trial: 8228208
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg once a day)
Trial: 28691132
Drug: Topical pure
RxNorm normalized name: Dream Pure BB Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pure emu oil
Trial: 25445556
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (SRT) at 66 Gy to the prostate bed, median 86 days after RP
Trial: 25445556
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (SRT)
Trial: 23806773
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (ZA) 4 mg administered within 28 days pre-HCT and at 3 and 6 months after HCT
Trial: 23806773
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (ZA)
Trial: 23806773
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcium carbonate and vitamin D supplements)
Trial: 11709314
Drug: Ritonavir-saquinavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-saquinavir (400 mg b.i.d.)
Trial: 11709314
Drug: Ritonavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (600 mg b.i.d.)
Trial: 3131251
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.i.d. (n = 40)
Trial: 3131251
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 2 g t.i.d. (n = 40)
Trial: 29657147
Drug: Subcutaneous Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous Abatacept (ABA) 125 mg/wk
Trial: 29657147
Drug: Intravenous Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Abatacept (ABA)
Trial: 28511482
Drug: ketofol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketofol (25 mg ketamine plus 25 mg propofol)
Trial: 28511482
Drug: ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine (0.25 mg/kg)
Trial: 28511482
Drug: propofol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol (0.25 mg/kg)
Trial: 23325368
Drug: SPST (independent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPST (independent of treatment)
Trial: 9264578
Drug: Intraperitoneal FUDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal FUDR + cisplatin (60 mg/m2 in 500 mL of NS)
Trial: 8495682
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole 40 mg the evening before surgery
Trial: 8495682
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole 40 mg 2 h before surgery
Trial: 8495682
Drug: Effervescent cimetidine
RxNorm normalized name: cimetidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent cimetidine 800 mg, 2 h before surgery
Trial: 8495682
Drug: No antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antacid (control group)
Trial: 28396179
Drug: Dance group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance group (60 minutes weekly for 40 weeks)
Trial: 28396179
Drug: Music group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music group (60 minutes weekly for 40 weeks)
Trial: 26568937
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 20 mg/kg
Trial: 26568937
Drug: Local bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local bupivacaine 2.5 ml 0.25%
Trial: 26568937
Drug: Intravenous pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pethidine 1 mg/kg
Trial: 21150717
Drug: WT1 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1 peptide vaccine and gemcitabine (GEM) combination therapy
Trial: 16799184
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline gel) dressing
Trial: 16799184
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma gel (after adjusting for wound size outliers)
Trial: 11167236
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bacitracin and neomycin
Trial: 8901773
Drug: rPF4 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPF4 (1.0 mg/kg IV over 2 minutes)
Trial: 8901773
Drug: Protamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine (50 mg IV over 10 minutes)
Trial: 7045754
Drug: Cefoxitin (2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2-dose course)
Trial: 27636836
Drug: Segmental traction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segmental traction therapy along with conventional physiotherapy, 15 sessions, 5 times a week for 3 weeks.
Trial: 21878941
Drug: cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib 20 mg per day plus carboplatin and paclitaxel
Trial: 21878941
Drug: cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib 20 mg per day followed by cediranib (concurrent plus maintenance)
Trial: 15455650
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine supplementation (240 ml/day) with MD
Trial: 15455650
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine supplementation (240 ml/day) with HFD
Trial: 11432629
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (MMM chemotherapy for ER-negative patients: methotrexate 30 mg/m2, mitozantrone 7 mg/m2, mitomycin 7 mg/m2 every three weeks for three months; Goserelin 3.75 mg monthly for premenopausal ER-positive patients; Formestane 250 mg every two weeks for postmenopausal ER-positive patients)
Trial: 3139776
Drug: Aluminum hydroxide-adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide-adsorbed vaccine (25 micrograms protein and polysaccharide administered intramuscularly)
Trial: 27625344
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg Q4W
Trial: 21192125
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment (Depotrex; Biotek, Inc.)
Trial: 19876678
Drug: 3-week 10-Hz
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week 10-Hz high frequency rTMS add on to antipsychotic therapy, 15 sessions per 3 weeks, 1,000 stimuli per session, stimulation intensity 110% of the individual motor threshold
Trial: 19876678
Drug: 3-week 10-Hz
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week 10-Hz high frequency rTMS add on to antipsychotic therapy
Trial: 1635654
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of lidocaine (xylocaine spray)
Trial: 6366248
Drug: Magnesium-containing Collins'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-containing Collins' 2 solution
Trial: 6366248
Drug: Magnesium-free Euro-Collins'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-free Euro-Collins' solution
Trial: 29246745
Drug: LSE liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSE liposomal gel
Trial: 20167430
Drug: Intradiscal methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal methylene blue injection
Trial: 25550680
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg.kg(‐1))
Trial: 25550680
Drug: Midazolam (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.025 μg.kg(‐1))
Trial: 18507654
Drug: Domperidone 30
RxNorm normalized name: domperidone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 30 mg daily
Trial: 18507654
Drug: Domperidone 60
RxNorm normalized name: domperidone 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 60 mg daily
Trial: 2370924
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (nifedipine)
Trial: 363104
Drug: N-n-propyl norapomorphine
RxNorm normalized name: n-propyl paraben
DrugBank: Propylparaben (DB14177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-n-propyl norapomorphine (NPA) with suboptimal doses of levodopa
Trial: 23683600
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of teriparatide (20 μg daily) and denosumab (60 mg every 6 months)
Trial: 25043459
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of teriparatide and denosumab
Trial: 8064552
Drug: Topical liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical liposome system bearing local anaesthetic lignocaine
Trial: 8064552
Drug: Conventional topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional topical application
Trial: 118360
Drug: Acetyldigoxin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyldigoxin (0.4 mg/day)
Trial: 118360
Drug: Acetyldigoxin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyldigoxin (0.4 mg/day) + Hydergin (3 mg/day)
Trial: 31238507
Drug: 60-g faecal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-g faecal microbiota transplantation (FMT)
Trial: 24718886
Drug: Panitumumab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab 6.0 mg/kg every 2 weeks + FOLFOX4
Trial: 15339468
Drug: Sansheng Huatan
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sansheng Huatan Decoction combined with chemotherapy
Trial: 12700441
Drug: sultamicillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sultamicillin (2 x 375 mg orally)
Trial: 12700441
Drug: amoxicillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin (3 x 500 mg orally)
Trial: 9627822
Drug: Implosive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implosive therapy (IT)
Trial: 8088611
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (ip): cisplatin 200 mg/m2 plus etoposide 350 mg/m2 every 4 weeks for six cycles.
Trial: 8088611
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (iv): cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks for six cycles.
Trial: 8088611
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (ip)